Anti-cytokeratin CAM5.2 (BD Biosciences) and CK8 Give No Remarkable Advantages to the Pancytokeratin Cocktail of Antibodies (AE1/AE3, CAM5.2, MNF116, CK8, and CK18) in Detecting Disseminated Tumor Cells in Biologic Subtypes of Stage I–III Breast Cancer Patients

首页> 外文期刊>Annals of Surgical Oncology >Anti-cytokeratin CAM5.2 (BD Biosciences) and CK8 Give No Remarkable Advantages to the Pancytokeratin Cocktail of Antibodies (AE1/AE3, CAM5.2, MNF116, CK8, and CK18) in Detecting Disseminated Tumor Cells in Biologic Subtypes of Stage I–III Breast Cancer Patients

【24h】

Anti-cytokeratin CAM5.2 (BD Biosciences) and CK8 Give No Remarkable Advantages to the Pancytokeratin Cocktail of Antibodies (AE1/AE3, CAM5.2, MNF116, CK8, and CK18) in Detecting Disseminated Tumor Cells in Biologic Subtypes of Stage I–III Breast Cancer Patients

机译：抗细胞角蛋白CAM5.2（BD Biosciences）和CK8在检测I期生物亚型中弥散性肿瘤细胞方面，抗体（AE1 / AE3，CAM5.2，MNF116，CK8和CK18）的全细胞角蛋白鸡尾酒没有明显优势。 III乳腺癌患者

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Annals of Surgical Oncology》 |2011年第s3期|p.261-262|共2页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献

1. Anti-cytokeratin CAM5.2 (BD Sciences) and CK8 Give No Remarkable Advantages to the Pancytokeratin Cocktail of Antibodies (AE1/AE3, CAM5.2, MNF116, CK8, and CK18) in Detecting Disseminated Tumor Cells in Biologic Subtypes of Stage I–III Breast Cancer Patients [J] . Annals of Surgical Oncology . 2011,第s3期

机译：抗细胞角蛋白CAM5.2（BD科学）和CK8在检测I期生物亚型中弥散性肿瘤细胞方面，抗体（AE1 / AE3，CAM5.2，MNF116，CK8和CK18）的全细胞角蛋白鸡尾酒没有明显优势。 III乳腺癌患者
2. Reply to "anti-CYTOKERATIN CAM5.2 recognized CK8 mainly, but not CK18: Comment on 'early assessment of axillary response with 18F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: Implications for surgical management of the axilla. Ann surg oncol. 2013;20(7):2227-35'" [J] . KoolenB.B., WesselingJ. Annals of surgical oncology . 2014,第2期

机译：回复“抗细胞角蛋白CAM5.2主要识别CK8，但不识别CK18：评论'II-III期乳腺癌新辅助化疗期间18F-FDG PET / CT对腋窝反应的早期评估：对腋窝外科治疗的意义。Ann surg oncol。2013; 20（7）：2227-35'“
3. Anti-cytokeratin CAM5.2 recognized CK8 mainly, but not CK18: Comment on "early assessment of axillary response with 18F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: Implications for surgical management of the axilla (Annals of surgical oncology doi: 10.1245/s10434-013-2902-0 (2013)" [J] . ChaoW.-R., HanC.-P. Annals of surgical oncology . 2014,第2期

机译：抗细胞角蛋白CAM5.2主要识别CK8，但不识别CK18：评论“ IIF-III期乳腺癌新辅助化疗期间早期评估18F-FDG PET / CT的腋窝反应：对腋窝外科治疗的意义（Annals of外科肿瘤学部：10.1245 / s10434-013-2902-0（2013）”
4. Disseminated Tumor Cells in Biologic Subtypes of Stage I–III Breast Cancer Patients [O] . Carolyn Hall, Savitri Krishnamurthy, Ashutosh Lodhi, -1

机译：在第一阶段I-III期乳腺癌患者的生物学亚型弥散性肿瘤细胞
5. Anti-cytokeratin CAM5.2 Recognized CK8 Mainly, but not CK18: Comment on “Early Assessment of Axillary Response with 18F-FDG PET/CT During Neoadjuvant Chemotherapy in Stage II–III Breast Cancer: Implications for Surgical Management of the Axilla. Annals of Surgical Oncology doi: 10.1245/s10434-013-2902-0 (2013)” [O] . Wan-Ru Chao, Chih-Ping Han 2013

机译：反科学研究CAM5.2主要识别CK8，但不是CK18：评论“在III阶段乳腺癌中新辅助化疗期间与18F-FDG PET / CT的腋窝响应的早期评估：对腋窝手术管理的影响。外科肿瘤学NOI：10.1245 / S10434-013-2902-0（2013）“

Anti-cytokeratin CAM5.2 (BD Biosciences) and CK8 Give No Remarkable Advantages to the Pancytokeratin Cocktail of Antibodies (AE1/AE3, CAM5.2, MNF116, CK8, and CK18) in Detecting Disseminated Tumor Cells in Biologic Subtypes of Stage I–III Breast Cancer Patients

著录项

相似文献

相关主题

期刊订阅